5745dd3a7dfae current research text box

Principle Investigators: Dr. David ZacksKEC ZacksDavid17033 copy

Disease: Retinitis Pigmentosa

Research Description: Certain mutations are a common cause of retinitis pigmentosa (RP), a rare ophthalmic condition resulting in night blindness, loss of peripheral vision and ultimately, profound vision loss. Currently, there are no approved therapies for patients with RP. Previous animal work by Dr. Zacks and his team have shown that drugs blocking a process called autophagy, or the breaking down and recycling of cell structures, may have potential for treating patients with RP caused by a specific mutation. Dr. Zacks and his team are testing a drug originally used to treat malaria that has already been repurposed to treat rheumatologic diseases. This proof of concept clinical trial will test the safety and tolerability of this drug in RP patients with a specific mutation, and will evaluate its ability to improve patients’ symptoms.

CWR Funding Role: Primary funder

CWR Funding Partner: Goldman Philanthropic Partnerships

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*

*required

If the link above doesn't work, please contact our Admin support at admin@cureswithinreach.org with your Full Name and Email Address to sign up!

 

Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Tuesday the 20th. Copyright 2018 Cures Within Reach.